How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/biap-bolus-and-8h-infusion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

bIAP bolus and 8h infusion — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

bIAP bolus and 8h infusion (bIAP bolus and 8h infusion) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Caspase-1 inhibitor. Area: Inflammatory diseases.

phase 3 Caspase-1 inhibitor Caspase-1 Inflammatory diseases Small molecule Live · refreshed every 30 min

Target snapshot

bIAP bolus and 8h infusion (bIAP bolus and 8h infusion) — Alloksys Life Sciences B.V.. bIAP is a caspase-1 inhibitor that blocks the activation of inflammatory caspases.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
bIAP bolus and 8h infusion TARGET	bIAP bolus and 8h infusion	Alloksys Life Sciences B.V.	phase 3	Caspase-1 inhibitor	Caspase-1
Epidiolex	CANNABIDIOL	Jazz Pharms Res	marketed		Caspase-1	2018-01-01
Epidiolex	Epidiolex	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	marketed		N-arachidonyl glycine receptor, Cannabinoid receptor 2, Caspase-1
ICE	ICE	MedImmune LLC	marketed	Caspase inhibitor	Caspase-1 (ICE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Caspase-1 inhibitor class)

Alloksys Life Sciences B.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bIAP bolus and 8h infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/biap-bolus-and-8h-infusion. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab